13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

2024 Speakers

We are seeking for speakers to share their experience, expertise, opinions and best practices in BioFIT conferences.
If you are interested, please contact us.

Learn more about BioFIT 2024 speakers

Over 60 international experts from academia, industry and biotech addressed issues to learn about the latest trends and explore hands-on approaches to tech transfer and open innovation in the field of Life Sciences, by sharing their experience and knowledge and keeping these goals in mind: Entail new partnerships, source innovative and competitive early-stage R&D projects, facilitate the emergence of collaborative projects and increase licensing opportunities in the field of Life Sciences.

Eric Wyart

Eric Wyart

Operational Director
BelgiumRéseau LiEU

Eric Wyart is the Operational Director of the LiEU Network, the network of technology and knowledge transfer offices of the French-speaking universities in Belgium (TTO/KTO). After completing his engineering degree from the Université Libre de Bruxelles, he began his career at Cenaero when the centre had just been created in 2002. He completed his doctoral thesis on the industrialization of crack propagation computation methods for aeronautical structures under the supervision of Professors Pardoen and Remacle at the Université catholique de Louvain.

Subsequently, he was successively in charge of the Metallic Structures & Processes and Computational Multiphysics Software Development teams at Cenaero. During this period, he contributed to the setting up of regional and European projects while pursuing actions to promote and raise awareness among companies. Activities he led until his departure for the R&D center of Plastic Omnium where he was in charge of the multiphysics design platform dedicated to fuel tanks.

Eric Wyart

Operational Director
BelgiumRéseau LiEU
Ester Caffarel-Salvador

Ester Caffarel-Salvador

Director, Strategic Innovation, Rare Diseases
USAChiesi USA

Ester is a multidisciplinary scientist with a background in biotechnology and bioengineering. After working in different roles across startups, pharma, and consulting, she is now the Director of Strategic Innovation at Chiesi USA, where she is scouting companies for partnerships or acquisitions that have innovative technologies to treat patients with rare diseases.

At MIT, Ester developed a pill to administer insulin orally, and was recognized as one of the 35 Innovators Under 35 by the MIT Technology Review in 2019. She serves as an advisor to various international startups. Ester speaks seven languages and is passionate about advocating on career development for women in science.

Ester Caffarel-Salvador

Director, Strategic Innovation, Rare Diseases
USAChiesi USA
Farzad Abdi-Dezfuli

Farzad Abdi-Dezfuli

Partner
NorwaySarsia

As one of the founders of Sarsia, and the principal analyst regarding life science investments, Farzad brings nearly 30 years of drug development expertise and management from large global pharma and early-stage start-ups. Farzad’s experience spans multiple national and global preclinical and clinical drug development initiatives at both administrative and Board levels. In addition to receiving training in entrepreneurial business financing from London Business School, Farzad obtained his doctoral education in pharmacology from the University of Edinburgh Medical School, UK and postdoctoral training from HaukelandUniversity Hospital Bergen, Norway.

Farzad Abdi-Dezfuli

Partner
NorwaySarsia
Gerald Law

Gerald Law

Chief Executive
United KingdomInnovation DB

Gerald has a background in Management Consultancy and academia. A London Business School alumnus with a Doctorate from Oxford University, he has experience of several start-ups and their exits, with considerable experience in building company executive boards, which has led him now to sit on VC investment committees, among other roles.

In 2010, he founded Innovation DB. Developed under contract from the UK MOD, IDB has now created an AI-enhanced data gathering system, that identifies, captures and describes emerging technologies, drawn from around 20,000 academic institutions. This provides an unparalleled dataset of research with real-world applications, that includes all biotech and pharma-related tech transfer activity to be found globally.

Gerald Law

Chief Executive
United KingdomInnovation DB
Jürgen Walkenhorst

Jürgen Walkenhorst

Manager Patents and Licenses
GermanyPROvendis GmbH

Jürgen studied biology/molecular biology in Osnabrück and Aberdeen (UK). After his diploma thesis at the EMBL in Heidelberg, he worked at Genentech, Inc. (USA). He undertook his PhD-thesis at the Max-Planck-Institute for Developmental Biology in Tübingen. He joined Cellzome AG (Heidelberg, now part of GSK) as the first employee where he was instrumental in setting up the company and was later responsible for IP-issues. After a stint in the patent department of Baxter AG in Vienna, he changed to technology transfer. At Austria Wirtschaftsservice GmbH, Vienna, he was managing life science inventions developed at Austrian universities.

In 2007, he moved to PROvendis, the central technology transfer agency of the universities of the German state of North Rhine-Westphalia, where during most of his time he served as a head of the Life sciences team. In between, he stayed for another one and a half years in Vienna, as head of technology transfer at the University of Vienna and furthermore for about one and a half years as Managing Director of Life Science Nord, the cluster organisation of the life science industry in the German states of Hamburg and Schleswig-Holstein.

He also holds a Master´s degree in Pharmaceutical Business Development and Licensing from the University of Manchester.

Jürgen Walkenhorst

Manager Patents and Licenses
GermanyPROvendis GmbH
Markus Lang

Markus Lang

Managing Director
GermanyDr Lang Consulting

Dr Lang Consulting GmbH brings 20 years of experience in pharmaceutical R&D, the successful development, manufacture and registration of biopharmaceutical drugs (focus on oncology and immunology).

Founder and Managing Director Dr. Markus A. Lang has profound leadership experience and successful P&L management of development portfolios in medium-sized companies as well as corporate environments in the biotech & pharmaceutical industry.

He made key contributions to successful development of several marketed drugs [Monjuvi®, Cyltezo®, Removab®, Pradaxa®]

As biotech entrepreneur Dr. Markus A. Lang supports companies in the areas of

  • Venture Development
  • C-Level Biotech Management. Organizational development
  • Preparation & execution of fundraising campaigns
  • Development and execution of drug development strategies
  • Lifecycle Focus: Late Discovery through (early) Preclinical to Phase I IND Readiness and/or phase II PoCC
  • Therapeutic entities: Biologics, ADCs and other moieties in primarily oncological and immunological disorders

Markus Lang

Managing Director
GermanyDr Lang Consulting
Matthieu Flourakis

Matthieu Flourakis

Team Lead “Strategic Partnerships & Stakeholder Management” & Senior Project Manager
BelgiumAkkodis

Matthieu Flourakis

Team Lead “Strategic Partnerships & Stakeholder Management” & Senior Project Manager
BelgiumAkkodis
Mikaël Le Clech

Mikaël Le Clech

Business Development Manager
FranceChemBioFrance

Mikaël Le Clech, PhD, is a Business Developer at ChemBioFrance – CNRS. He leads several activities ranging from forging alliances with industrial partners to communication. Before joining ChemBioFrance, Mikaël held various positions in the field of biotechnology R&D, entrepreneurship and quality assurance. He was also head of the monoclonal antibody platform at the Max Planck Institute of Biochemistry, Munich. Mikaël holds a PhD from the University of Montpellier.

Mikaël Le Clech

Business Development Manager
FranceChemBioFrance
Olivier Martinon

Olivier Martinon

Vice President External Innovation
USAZoetis

Olivier Martinon is Vice President, External Innovation at Zoetis where he leads the team responsible for identifying and developing strategic partnerships that enhance the company’s own research and development pipeline. He joined Zoetis via its legacy companies in 2006, and has previously held roles at the company including Executive Research Director for Zoetis’ global therapeutics group and led portfolio projects and mentored researchers critical to securing global approvals for our new monoclonal antibodies (mAbs) to control pain associated with osteoarthritis in dogs and cats. He also previously led the livestock therapeutic area identifying key external partners to advance that portfolio, was the original champion in creating the biotherapeutic discipline within Zoetis’ Veterinary Medicine Research & Development organization. Dr. Martinon completed his veterinary studies in Paris-Alfort France in 1990, and he studied molecular biology at CIRAD before moving to a DEA/MS in Biotechnology from Paris VI. He then pursued a cursus in Immunology for three years with Institut Pasteur Professor. Olivier is French and American having grown up in Lyon (France) and moved to the U.S. in 2002. He and his wife live near Grand Rapids, Michigan and have three grown sons.

Olivier Martinon

Vice President External Innovation
USAZoetis
Patrick di Stefano

Patrick di Stefano

Industrial Relations Manager and Technology Transfer Expert
BelgiumUniversité libre de Bruxelles

Patrick Di Stefano is a Technology Transfer Officer at the Knowledge Transfer Office of Université Libre de Bruxelles (ULB-KTO). Throughout his carrier Patrick acquired an outstanding experience in all the fields of knowledge and technology transfer and has been strongly involved into the creation of several ULB spin-off companies. Patrick is a member of the Board of ULB and several research centers. He is also a Senior Lecturer at the ULB Faculty of Pharmacy. Patrick holds the degree of Ph.D. (Biochemistry) and is a RTTP (Registered Technology Transfer Professional) fellow since 2011.

Patrick di Stefano

Industrial Relations Manager and Technology Transfer Expert
BelgiumUniversité libre de Bruxelles
Paul Bravetti

Paul Bravetti

CEO
FranceBrenus Pharma

Paul Bravetti (PharmD, HEC Paris) is a strategic executive with a particular interest in scientific innovation and entrepreneurial adventures.

With his international experience in major pharmaceutical companies, which has shaped his understanding of the biopharmaceutical industry, he has successfully led the launches of therapeutics in immuno-oncology and biomolecular diagnostics across Europe and Asia. He joined Brenus Pharma in 2020 and became Chief Executive Officer in 2022 with a clear vision, mission, and leadership to address current unmet needs and make a significant impact for cancer patients.”

Brenus Pharma is a French clinical-stage biotech developing a pioneering technology platform, Stimulated-Tumor-Cell (STC).

STC is designed to generate ‘off-the-shelf’ and ‘first-in-class’ therapeutic cancer vaccine leading the way to a new precision medicine in immuno-oncology.

Brenus Pharma is on the brink of a breakthrough and will start its first-in-human study in 2024 in colorectal cancer, 2nd cause of cancer-related deaths worldwide.

We are building a strong portfolio in solid tumors, leveraging our patented STC platform, to change a paradigm in oncology.

Paul Bravetti

CEO
FranceBrenus Pharma
Tamar Raz

Tamar Raz

CEO
IsraelHadasit

Dr. Tamar Raz has nearly two decades of experience in technology transfer and an impressive track record of bringing medical innovations from the lab to the marketplace. Prior to joining Hadasit, she served as VP of Marketing and Strategy at Ramot, the technology transfer company of Tel Aviv University. Tamar was the founder and CEO of Allergene Ltd, an Israeli drug development start-up company. She received her MSc and PhD in cell biology from the Tel Aviv University School of Medicine.

Tamar Raz

CEO
IsraelHadasit

Contact

Eline Delcroix

Scroll to Top
  • No products in the cart.